Calidi Biotherapeutics Inc (CLDI)

Currency in USD
6.1800
-1.0700(-14.76%)
Closed·
After Hours
6.1300-0.0500(-0.81%)
·
CLDI Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CLDI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.90007.1300
52 wk Range
2.432446.6800
Key Statistics
Prev. Close
7.25
Open
7.13
Day's Range
5.9-7.13
52 wk Range
2.4324-46.68
Volume
264.67K
Average Volume (3m)
1.43M
1-Year Change
-59.99%
Book Value / Share
2.48
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CLDI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
120.0048
Upside
+1,841.83%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Calidi Biotherapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Calidi Biotherapeutics Inc Company Profile

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clinical studies; CLD-301 for multiple indications, which is in preclinical studies; and CLD-400 for certain lung cancer and metastatic solid tumors. The company also offers oncolytic virus platforms, such as NeuroNova, SuperNova, and RTNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.

Compare CLDI to Peers and Sector

Metrics to compare
CLDI
Peers
Sector
Relationship
P/E Ratio
−1.0x−4.7x−0.5x
PEG Ratio
−0.010.000.00
Price/Book
3.2x5.0x2.6x
Price / LTM Sales
-10.0x3.3x
Upside (Analyst Target)
-144.8%42.8%
Fair Value Upside
Unlock−3.1%6.5%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 120.0048
(+1,841.83% Upside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.18 / -0.25
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

CLDI Income Statement

People Also Watch

38.44
BMNR
+15.42%
2.880
PROK
-9.43%
0.040
NCNA
-4.94%
0.95
KLTO
-2.96%

FAQ

What Stock Exchange Does Calidi Biotherapeutics Trade On?

Calidi Biotherapeutics is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Calidi Biotherapeutics?

The stock symbol for Calidi Biotherapeutics is "CLDI."

What Is the Calidi Biotherapeutics Market Cap?

As of today, Calidi Biotherapeutics market cap is 21.94M.

What Is Calidi Biotherapeutics's Earnings Per Share (TTM)?

The Calidi Biotherapeutics EPS (TTM) is -18.64.

From a Technical Analysis Perspective, Is CLDI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Calidi Biotherapeutics Stock Split?

Calidi Biotherapeutics has split 2 times.

How Many Employees Does Calidi Biotherapeutics Have?

Calidi Biotherapeutics has 28 employees.

What is the current trading status of Calidi Biotherapeutics (CLDI)?

As of 06 Aug 2025, Calidi Biotherapeutics (CLDI) is trading at a price of 6.18, with a previous close of 7.25. The stock has fluctuated within a day range of 5.90 to 7.13, while its 52-week range spans from 2.43 to 46.68.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.